Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2-3/2010

01-04-2010

Currents Concepts on the Immunopathology of Amyloidosis

Authors: Anupama Bhat, Carlo Selmi, Stanley M. Naguwa, Gurtej S. Cheema, M. Eric Gershwin

Published in: Clinical Reviews in Allergy & Immunology | Issue 2-3/2010

Login to get access

Abstract

Amyloidosis is defined as the extracellular accumulation at systemic or organ-specific level of insoluble low molecular weight protein fibrils manifesting a beta pleated sheet configuration and a characteristic staining pattern. Several different types of proteins may lead to this phenomenon, and amyloidosis is defined by the biochemical nature of the protein in the deposits and further classified according to whether the deposits are localized or systemic, acquired or inherited, and by the resulting clinical phenotype. Amyloidosis includes subtypes such as light chain, associated with serum amyloid A protein, heritable and familial forms, dialysis-related disease, and organ-specific conditions. The pathogenesis and clinical features of these clinical and pathological entities will be critically discussed in this review article.
Literature
1.
2.
3.
Gallo G, Wisniewski T, Choi-Miura NH, Ghiso J, Frangione B (1994) Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 145:526–530PubMed
4.
Rajkumar SV (2008) Pathogensis and clinical features of primary (AL) amyloidosis and light and heavy chain deposition diseases. In UpToDate online
5.
Husby G, Stenstad T, Magnus JH, Sletten K, Nordvag BY, Marhaug G (1994) Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 70:2–9CrossRefPubMed
6.
Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92:4299–4303CrossRefPubMed
7.
Kaplan B, Ramirez-Alvarado M, Sikkink L, Golderman S, Dispenzieri A, Livneh A, Gallo G (2009) Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 144:705–715CrossRefPubMed
8.
Gertz MA, Lacy MQ, Dispenzieri A (1999) Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 74:490–494CrossRefPubMed
9.
Rajkumar SV, Dispenzieri A, Kyle RA (2006) Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 81:693–703CrossRefPubMed
10.
Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R (2003) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101:3801–3808CrossRefPubMed
11.
Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM et al (2008) Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 112:1931–1941CrossRefPubMed
12.
Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA (2009) Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol (in press)
13.
Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103:544–549CrossRefPubMed
14.
Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S et al (2009) Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55:499–504CrossRefPubMed
15.
van Gameren I, Hazenberg BP, Bijzet J, van Rijswijk MH (2006) Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 54:2015–2021CrossRefPubMed
16.
Ansari-Lari MA, Ali SZ (2004) Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol 30:178–181CrossRefPubMed
17.
Bogov B, Lubomirova M, Kiperova B (2008) Biopsy of subcutaneus fatty tissue for diagnosis of systemic amyloidosis. Hippokratia 12:236–239PubMed
18.
Kyle RA, Bayrd ED (1975) Amyloidosis: review of 236 cases. Medicine (Baltimore) 54:271–299
19.
20.
Dominguez S, Wienberg P, Claros P, Claros A, Vila J (1996) Primary localized nasopharyngeal amyloidosis. A case report. Int J Pediatr Otorhinolaryngol 36:61–67CrossRefPubMed
21.
Dimopoulos M, Kastritis E (2008) High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further? Leuk Lymphoma 49:4–5CrossRefPubMed
22.
Zhou P, Teruya-Feldstein J, Lu P, Fleisher M, Olshen A, Comenzo RL (2008) Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood 111:549–557CrossRefPubMed
23.
Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97:341–344CrossRefPubMed
24.
Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, Maurer MS, Steingart RM, Cohen AD, Comenzo RL (2008) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 143:369–373CrossRefPubMed
25.
Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, Fleisher M, Hoffman J, Jhanwar S, Young JW et al (2008) CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 111:3403–3406CrossRefPubMed
26.
Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, Tannock LR (2008) Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 173:1902–1910CrossRefPubMed
27.
Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, Johansen KL (2008) Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) 13:593–600CrossRef
28.
Westermark GT, Westermark P (2009) Serum amyloid A and protein AA: Molecular mechanisms of a transmissible amyloidosis. FEBS Lett (in press)
29.
Milner J, Ward J, Keane-Myers A, Min B, Paul WE (2007) Repertoire-dependent immunopathology. J Autoimmun 29:257–261CrossRefPubMed
30.
Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75CrossRefPubMed
31.
Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66:9–26CrossRefPubMed
32.
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371CrossRefPubMed
33.
Westermark GT, Westermark P, Sletten K (1987) Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab Invest 57:57–64PubMed
34.
Kluve-Beckerman B, Manaloor JJ, Liepnieks JJ (2002) A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 46:1905–1913CrossRefPubMed
35.
Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S, Ataman R, Akpolat T, Ok E, Sen S et al (2002) A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 17:2003–2005CrossRefPubMed
36.
Momohara S, Okamoto H, Yamanaka H (2008) Chondrocyte of rheumatoid arthritis serve as a source of intra-articular acute-phase serum amyloid A protein. Clin Chim Acta 398:155–156CrossRefPubMed
37.
Ritta Koivuniemi LP, Suomalainen R, Tornroth T (2008) 4Amyloidosis is frequently undetected in patients with rhematoid arthritis. Amyloid 15:262–268CrossRef
38.
David J, Vouyiouka O, Ansell BM, Hall A, Woo P (1993) Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 11:85–90PubMed
39.
Kelly KJ, Kluve-Beckerman B, Dominguez JH (2009) Acute-phase response protein serum amyloid A stimulates renal tubule formation: studies in vitro and in vivo. Am J Physiol Renal Physiol 296:F1355–F1363CrossRefPubMed
40.
Simms RW, Prout MN, Cohen AS (1994) The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 8:627–634CrossRefPubMed
41.
Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34:371–373PubMed
42.
Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43:227–253CrossRefPubMed
43.
Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 70:246–256
44.
Melikoglu M, Altiparmak MR, Fresko I, Tunc R, Yurdakul S, Hamuryudan V, Yazici H (2001) A reappraisal of amyloidosis in Behcet's syndrome. Rheumatology (Oxford) 40:212–215CrossRef
45.
Nakamura S, Morishita M, Yang CL, Utsumi K, Takada H, Furuhashi K, Sugiura H (2006) An elderly female who survived more than 30 years following a diagnosis of Takayasu's arteritis, complicated by fatal intestinal amyloidosis. Clin Rheumatol 25:907–910CrossRefPubMed
46.
Cruz I, Oliveira AP, Lopes JM, Ricardo JL, de Freitas J (1993) Whipple's disease and renal amyloidosis. Am J Gastroenterol 88:1954–1956PubMed
47.
Escriba A, Morales E, Albizua E, Herrero JC, Ortuno T, Carreno A, Dominguez-Gil B, Praga M (2000) Secondary (AA-type) amyloidosis in patients with polymyalgia rheumatica. Am J Kidney Dis 35:137–140CrossRefPubMed
48.
Robinson RD, Murphy EL, Wilks RJ, Neva FA, Terry SI, Hanchard B, Figueroa JP, Blattner WA (1991) Gastrointestinal parasitic infection in healthy Jamaican carriers of HTLV-I. J Trop Med Hyg 94:411–415PubMed
49.
50.
Wong BC, Wong KL, Ip MS, Wang EP, Chan KW, Cheng LC (1994) Sjogren's syndrome with amyloid A presenting as multiple pulmonary nodules. J Rheumatol 21:165–167PubMed
51.
Redline S, Pack AI (2006) Rising to meet an unmet public health need: sleep medicine and the pulmonary community. Am J Respir Crit Care Med 174:487–488CrossRefPubMed
52.
Van Der Hilst JCH, Drenth JP (2005) Serum amyloid A serum concentratins and genotype do not explain low incidence of amyloidosis in Hyper -IgD syndrome. Amyloid 12:115–119CrossRefPubMed
53.
Picken MM, Pelton K, Frangione B, Gallo G (1987) Primary amyloidosis A. Immunohistochemical and biochemical characterization. Am J Pathol 129:536–542PubMed
54.
Jager PL, Hazenberg BP, Franssen EJ, Limburg PC, van Rijswijk MH, Piers DA (1998) Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 39:699–706PubMed
55.
Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508–513PubMed
56.
Kumar-Singh S (2009) Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. Int J Mol Sci 10:1872–1895CrossRefPubMed
57.
Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, Lohse P, Buttner J, Schmidt H, Rocken C (2009) Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 11:257–262CrossRefPubMed
58.
Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216:253–261CrossRefPubMed
59.
Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 20:444–451CrossRefPubMed
60.
Dardiotis E, Koutsou P, Papanicolaou EZ, Vonta I, Kladi A, Vassilopoulos D, Hadjigeorgiou G, Christodoulou K, Kyriakides T (2009) Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid 16:32–37CrossRefPubMed
61.
Nagasaka T, Togashi S, Watanabe H, Iida H, Nagasaka K, Nakamura Y, Miwa M, Kobayashi F, Shindo K, Shiozawa Z (2009) Clinical and histopathological features of progressive-type familial amyloidotic polyneuropathy with TTR Lys54. J Neurol Sci 276:88–94CrossRefPubMed
62.
Hornsten R, Suhr OB, Jensen SM, Wiklund U (2008) Outcome of heart rate variability and ventricular late potentials after liver transplantation for familial amyloidotic polyneuropathy. Amyloid 15:187–195CrossRefPubMed
63.
Robin J, Meyers S, Nahlawi M, Puthumana J, Lomasney J, Mehlman D, Rigolin V, Davidson C (2008) Accelerating restrictive cardiomyopathy after liver transplantation in a patient with familial amyloidotic polyneuropathy: a case report. J Med Case Reports 2:35CrossRefPubMed
64.
Hou X, Aguilar MI, Small DH (2007) Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 274:1637–1650CrossRefPubMed
65.
Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78:74–82PubMed
66.
Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466–473CrossRefPubMed
67.
Jacobson DR, Ittmann M, Buxbaum JN, Wieczorek R, Gorevic PD (1997) Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports. Tex Heart Inst J 24:45–52PubMed
68.
Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, Seward JB, Tajik AJ (1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135–1141PubMedCrossRef
69.
Hawkins PN (2003) Hereditary systemic amyloidosis with renal involvement. J Nephrol 16:443–448PubMed
70.
Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD (2003) Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int 64:11–16CrossRefPubMed
71.
Maury CP, Sletten K, Totty N, Kangas H, Liljestrom M (1997) Identification of the circulating amyloid precursor and other gelsolin metabolites in patients with G654A mutation in the gelsolin gene (Finnish familial amyloidosis): pathogenetic and diagnostic implications. Lab Invest 77:299–304PubMed
72.
Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE (2003) Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 10:160–184PubMed
73.
Tutaj M, Szczepanik M (2007) Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun 28:208–215CrossRefPubMed
74.
Otsubo S, Kimata N, Okutsu I, Oshikawa K, Ueda S, Sugimoto H, Mitobe M, Uchida K, Otsubo K, Nitta K et al (2009) Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 24:1593–1598CrossRefPubMed
75.
Kim J, Motomiya Y, Ueda M, Nakamura M, Misumi Y, Saito S, Ikemizu S, Misumi S, Ota K, Shinriki S et al (2008) Role of conformational change in the C-terminus of beta2-microglobulin in dialysis-related amyloidosis. Ann Clin Biochem 45:489–495CrossRefPubMed
76.
Naiki H, Yamamoto S, Hasegawa K, Yamaguchi I, Goto Y, Gejyo F (2005) Molecular interactions in the formation and deposition of beta2-microglobulin-related amyloid fibrils. Amyloid 12:15–25CrossRefPubMed
77.
78.
Noel LH, Zingraff J, Bardin T, Atienza C, Kuntz D, Drueke T (1987) Tissue distribution of dialysis amyloidosis. Clin Nephrol 27:175–178PubMed
79.
Saito A, Gejyo F (2006) Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients. Ther Apher Dial 10:316–320CrossRefPubMed
80.
Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284:4749–4753CrossRefPubMed
81.
Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 10:94–100CrossRefPubMed
82.
Gorevic PD (2008) Genetic factos in the amyloid dissseases. In UpToDate online
83.
Lleo A, Berezovska O, Growdon JH, Hyman BT (2004) Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 12:146–156PubMed
84.
Tucker SM, Borchelt DR, Troncoso JC (2008) Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J Neuropathol Exp Neurol 67:30–40CrossRefPubMed
85.
86.
Kristen AV, Schnabel PA, Winter B, Helmke BM, Longerich T, Hardt S, Koch A, Sack FU, Katus HA, Linke RP et al (2009) High prevalence of amyloid in 150 surgically removed heart valves-a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol (in press)
87.
88.
Lewis JE, Olsen KD, Kurtin PJ, Kyle RA (1992) Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg 106:372–377PubMed
89.
90.
Blank M, Gershwin ME (2008) Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 30:1–4CrossRefPubMed
Metadata
Title
Currents Concepts on the Immunopathology of Amyloidosis
Authors
Anupama Bhat
Carlo Selmi
Stanley M. Naguwa
Gurtej S. Cheema
M. Eric Gershwin
Publication date
01-04-2010
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2-3/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8163-9

Other articles of this Issue 2-3/2010

Clinical Reviews in Allergy & Immunology 2-3/2010 Go to the issue

OriginalPaper

Mycobacterium Tuberculosis, Autoimmunity, and Vitamin D

OriginalPaper

Mold and Human Health: Separating the Wheat from the Chaff

OriginalPaper

Sarcoidosis Presenting as “Corset-like” Myelopathy: A Description of Six Cases and Literature Review

OriginalPaper

Lupus and Pregnancy—15 Years of Experience in a Tertiary Center

OriginalPaper

Antifibrosis: To Reverse the Irreversible

OriginalPaper

The Premenstrual Syndrome and Fibromyalgia—Similarities and Common Features
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits